Bayer to develop Coagulin-B with Avigen

Bayer (DAX:BAYG) received exclusive worldwide marketing and distribution rights to AVGN's Coagulin-B adeno-associated virus (AAV) gene therapy to treat hemophilia B, a deficiency in clotting Factor IX...